Chemotherapy at the end of life in colorectal and pancreatic cancer: Real-world data and trends over time.
Catherine Dunn, Belinda Lee, Jeremy David Shapiro, Rachel Wong, Grace Gard, Michael Michael, Wei Hong, Matthew E Burge, Vanessa Wong, Ben Thomson, Sumitra Ananda, Sue-Anne McLachlan, Brett Knowles, Mehdrad Nikfarjam, Jeanne Tie, Ross Jennens, Joseph James McKendrick, Margaret Lee, Suzanne Kosmider, Peter Gibbs
Journal of Clinical Oncology | American Society of Clinical Oncology (ASCO) | Published : 2021
e18723 Background: Chemotherapy at the end of life (CEOL) is widely accepted as an indicator of aggressive care. However, the evidence is limited primarily to single-centre experiences, with no consensus regarding acceptable benchmarks for CEOL, nor how this may be changing over time and with novel treatment options. We describe ‘real world’ CEOL in two large, multisite Australian registries of metastatic colorectal cancer (mCRC) and both locally advanced and metastatic pancreatic cancer (PC). Methods: Data was analysed from the TRACC and PURPLE registries, two large prospective multisite Australian cancer registries collecting prospective demographic, tumour, treatment and outcome data for..View full abstract